Aripiprazole lauroxil - Alkermes

Drug Profile

Aripiprazole lauroxil - Alkermes

Alternative Names: ALNCD; ALKS-9070; ALKS-9072; Aripiprazole Lauroxil NanoCrystal® Dispersion; ARISTADA; ARISTADA INITIO

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alkermes
  • Developer Alkermes plc
  • Class Antipsychotics; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Schizophrenia

Most Recent Events

  • 02 Jul 2018 Alkermes plc plans to launch ALNCD (ARISTADA INITIO™) for Schizophrenia in the US by mid of July 2018
  • 02 Jul 2018 Registered for Schizophrenia (New delivery system) in USA (IM)
  • 16 Nov 2017 FDA assigns PDUFA action date of 30/06/2018 for Aripiprazole Lauroxil NanoCrystal® Dispersion for Schizophrenia (New delivery system)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top